Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

BARDA - ASPR / DAAPPO / BARDA DCMA

Contract Value

Not provided

Codes & Classification
Solicitation Number

75A50126R00001_RFP_NPIVS_27

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AN12

Additional Details
Set Aside

NONE

Place of Performance

Washington, District of Columbia, UNITED STATES

SourceSAM
The Biomedical Advanced Research and Development Authority (BARDA), operating under the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, has issued a Request for Proposals (RFP) seeking qualified contractors to support the ongoing Vaccine Medical Countermeasures (MCMs) for Pandemic Influenza Preparedness and Response Program. This solicitation, identified as 75A50126R00001_RFP_NPIVS_27, is a critical component of the federal government’s strategy to enhance national readiness and response capabilities in the face of pandemic influenza and other viral threats with pandemic potential. The primary objective of this procurement is to secure comprehensive contractor support for the development, production, and supply of medical countermeasures—specifically vaccines, antigens, and adjuvants—intended for both pandemic preparedness and rapid response during public health emergencies. Contractors will be responsible for providing all necessary services, qualified personnel, materials, supplies, equipment, and facilities (with a preference for U.S.-based facilities) not otherwise supplied by the U.S. Government. The scope of work includes the production of antigens and vaccines against influenza viruses or other viruses with pandemic potential, as well as the development of antigens, adjuvants, and/or vaccines to support U.S. Government efforts to improve influenza vaccines, provided feasibility data is available. A key deliverable under this contract is the generation and submission of all relevant data required to support rapid regulatory decisions and manufacturing readiness. This includes, but is not limited to, analytical, nonclinical, clinical, and chemistry, manufacturing, and controls (CMC) data, which must be submitted to the U.S. Food and Drug Administration (FDA). The requirement for data generation and submission extends to both pandemic and interpandemic periods, ensuring continuous preparedness and regulatory compliance. To be eligible for award, offerors must meet stringent mandatory qualification requirements. Specifically, offerors must demonstrate the capability to produce vaccines against influenza and influenza strains with pandemic potential. This can be evidenced by either holding a current U.S. influenza vaccine license or having developed an influenza vaccine, as demonstrated by the submission of a Biologics License Application (BLA) for a seasonal or pandemic influenza vaccine. These requirements ensure that only experienced and qualified entities with proven manufacturing and regulatory expertise are considered for this critical national security initiative. The procurement is classified under NAICS code 541714, “Research and Development in Biotechnology (except Nanobiotechnology),” and product service code AN12. There are no set-aside restrictions for this solicitation, making it open to all qualified entities regardless of size. The primary place of performance is Washington, District of Columbia, United States. The contracting activity is managed by BARDA - ASPR / DAAPPO / BARDA DCMA, a federal office dedicated to advancing medical countermeasure development and procurement. Interested parties should direct all inquiries and proposal submissions to the primary contact, Laura Saddison, at [email protected]. The solicitation was posted on October 26, 2026, and remains active, with responses due by November 20, 2026. Full solicitation details, including proposal submission instructions and mandatory requirements, are provided in attachments 01-21 available via the official notice on SAM.gov (Opportunity ID: a63ab723a93d4ac5952e6b64222262ab). This opportunity represents a significant and ongoing commitment by the U.S. Government to bolster pandemic preparedness and response infrastructure. Contractors with established capabilities in influenza vaccine development, manufacturing, and regulatory submission are encouraged to review the full solicitation and consider participation in this vital public health initiative.
Documents26